ConjuGon: The Coasts are Calling ConjuGon to Present at Key Biotech Forums

Contact Sal
Braico at (608) 441-2890 or [email protected]

FOR IMMEDIATE RELEASE

October 11, 2004 Madison, WI – ConjuGonT announces today that it was
selected to present at two prestigious venture capital conferences this
fall on both coasts.

Christopher Price, CEO, will present at the BIO Emerging Company
Investor Forum in San Francisco on October 14-15 and the Bio-Life-Tech
Conference in Baltimore on October 13. Both venues bring together
promising biotechnology companies and leading investors.

“ConjuGon’s technology is drawing a lot of interest on both coasts, as
well as in the Midwest and globally,” said Price. “We are honored to be
chosen to present at these conferences.”

ConjuGon has raised nearly $2.8 million in seed capital, including $1.9
million from angel investors, and $290,000 in economic development loans
from the Madison Development Corporation and the Wisconsin Department of
Commerce. The company has also been awarded $600,000 in Small Business
Innovation Research (SBIR) grants from the National Science Foundation.

ConjuGon is developing fundamentally new technologies to combat the
growing epidemic of antibiotic-resistant bacteria. Antibiotic resistance
is a medical crisis, globally responsible for hundreds of thousands of
deaths each year. ConjuGon’s core technology is a new way to kill
unwanted and even multi-drug resistant bacteria. The company, which has
an experienced staff of eight, is located in the MG&E Innovation Center
in Madison.